Skip to main content

Table 1 Patient characteristics by SSRI use

From: Selective serotonin reuptake inhibitor use and breast cancer survival: a population-based cohort study

  All patients SSRI use
Non-user User
Number of patients 23,669 18,885 4784
Year of diagnosis
 1998–2002 5738 (24.2%) 4491 (23.8%) 1247 (26.1%)
 2003–2007 8776 (37.1%) 6911 (36.6%) 1865 (39.0%)
 2008–2012 9155 (38.7%) 7483 (39.6%) 1672 (34.9%)
Mean age at diagnosis (SD) 61.9 (14.0) 62.6 (13.9) 58.9 (13.9)
 0–49 4774 (20.2%) 3479 (18.4%) 1295 (27.1%)
 50–59 5913 (25.0%) 4590 (24.3%) 1323 (27.7%)
 60–69 5955 (25.2%) 4903 (26.0%) 1052 (22.0%)
 70–79 4037 (17.1%) 3357 (17.8%) 680 (14.2%)
Deprivation quintile
 1 (least deprived) 6026 (25.5%) 4923 (26.1%) 1103 (23.1%)
 2 6087 (25.7%) 4923 (26.1%) 1164 (24.3%)
 3 4873 (20.6%) 3875 (20.5%) 998 (20.9%)
 4 3941 (16.7%) 3072 (16.3%) 869 (18.2%)
 5 (most deprived) 2733 (11.6%) 2084 (11.0%) 649 (13.6%)
 Missing (n) 9 8 1
Comorbidities
 Chronic pulmonary disease 2716 (11.5%) 2033 (10.8%) 683 (14.3%)
 Diabetes 1456 (6.2%) 1141 (6.0%) 315 (6.6%)
 Renal disease 1076 (4.5%) 914 (4.8%) 162 (3.4%)
 Cerebrovascular disease 650 (2.7%) 498 (2.6%) 152 (3.2%)
 Congestive heart disease 345 (1.5%) 287 (1.5%) 58 (1.2%)
 Peripheral vascular disease 264 (1.1%) 211 (1.1%) 53 (1.1%)
 Myocardial infarction 250 (1.1%) 199 (1.1%) 51 (1.1%)
 Peptic ulcer disease 238 (1.0%) 179 (0.9%) 59 (1.2%)
 Liver disease 45 (0.2%) 35 (0.2%) 10 (0.2%)
Hot flushes 1693 (7.2%) 1024 (5.4%) 669 (14.0%)
Pre-diagnosis confounder medication use
 Hormone replacement therapy 7002 (29.6%) 5233 (27.7%) 1769 (37.0%)
 Oral contraceptive 6009 (25.4%) 4454 (23.6%) 1555 (32.5%)
Treatment
 Surgery 19,218 (81.2%) 15,212 (80.6%) 4006 (83.7%)
 Tamoxifen 10,051 (42.5%) 8006 (42.4%) 2045 (42.7%)
 Radiotherapy 8320 (35.2%) 6683 (35.4%) 1637 (34.2%)
 Chemotherapy 6774 (28.6%) 5213 (27.6%) 1561 (32.6%)
 Aromatase inhibitors 4975 (21.0%) 4094 (21.7%) 881 (18.4%)
Grade
 1 3780 (17.9%) 2988 (17.8%) 792 (18.5%)
 2 10,282 (48.7%) 8210 (48.8%) 2072 (48.3%)
 3 7039 (33.3%) 5616 (33.4%) 1423 (33.2%)
 4 19 (0.1%) 18 (0.1%) 1 (0.0%)
 Missing (n) 2549 2053 496
Stage
 1 4791 (49.0%) 3812 (48.8%) 979 (49.7%)
 2 3936 (40.2%) 3127 (40.0%) 809 (41.1%)
 3 748 (7.6%) 623 (8.0%) 125 (6.4%)
 4 309 (3.2%) 254 (3.2%) 55 (2.8%)
 Missing (n) 13,885 11,069 2816
Smoking
 No 12,975 (61.3%) 10,653 (63.4%) 2328 (53.2%)
 Ex 4677 (22.1%) 3696 (22.0%) 976 (22.3%)
 Yes 3526 (16.6%) 2457 (14.6%) 1068 (24.4%)
 Missing (n) 2491 2079 412
Alcohol
 No 3406 (19.7%) 2711 (19.7%) 697 (19.5%)
 Ex 347 (2.0%) 252 (1.8%) 95 (2.7%)
 Yes 13,577 (78.3%) 10,788 (78.5%) 2787 (77.9%)
 Missing (n) 6339 5134 1205
Obesity
 Normal 7723 (41.0%) 6178 (41.5%) 1548 (39.3%)
 Overweight 6326 (33.6%) 4999 (33.6%) 1325 (33.6%)
 Obese 4776 (25.4%) 3707 (24.9%) 1068 (27.1%)
 Missing (n) 4844 4001 843
  1. Data presented as n (%) unless otherwise indicated
  2. SSRI selective serotonin reuptake inhibitor, SD standard deviation